Table 2.

Outcome parameters

Engraftment
Median transplant cell dose × 107/kg (range)	1.8 (0.17 – 8.59)
Median days to sustaineda ANC ≥ 500 (range)	12 (8 – 30)
Median days to sustainedb platelet count ≥ 20,000 (range)	22 (10 – 170)
GVHD
Acute, grade I	3c
Acute, grade II	7
Acute, grade III	4
Acute, grade IV	0
Chronic, limited	5c
Chronic, extensive	3d
Causes of death
Relapse	8
Infectious causes	3 CMV pneumonitis
	7 othere
GVHD and secondary complications	8
Interstitial pneumonitis	2
Lung cancer	1f
Post-transplant EBV-LPD	4

^asustained denotes 3 consecutive days;

^bsustained denotes 3 consecutive days and platelet transfusion independent;

^cincluding one patient post-DLI;

^dincluding 2 patients post DLI;

^eother infections: sepsis (no identified organism) – n=2, E Coli sepsis – n=1, disseminated pseudomonas aeruginosa – n=1, disseminated adenovirus – n=1, toxoplasmosis – n=1; fever with no identified organism – n=1;

^fthe patient who died of lung cancer was also found to have relapsed mantle cell lymphoma on a mediastinal lymph node biopsy.